p53, guardian of the genome
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p53, famously known as the ‘Guardian of the genome’ plays a key role in manifestation of cellular senescence via several different mechanisms (Lane, 1992; Kastenhuber and Lowe, 2017).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Lane, 1992
In the citing paper
“p53 is an crucial tumor suppressor that is mutated in more than 50% of human cancers”
From USP10 Regulates p53 Localization and Stability by Deubiquitinating p53 (2010) · cites this paper as Lane, 1992
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells.
Maltzman, W., & Czyzyk, L. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.9.1689 · Cited by 893
Research works printed but not linked: 3
- Sturzbecher, H.-W. Oncogene (in the press).
- Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R. W. Cancer Res. 51, 6304–6311 (1991).
- Bischoff, F. Z. et al. Cancer Res. 50, 7979–7984 (1990).
Cited by
Items 901–1,000 of 1,031
Targeting the DNA damage response for cancer therapy
Powell, S. N., & Bindra, R. S. (2009) · DNA repair · doi:10.1016/j.dnarep.2009.04.011 · Cited by 92
Ribosomal proteins as novel players in tumorigenesis
Heras-Rubio, A. D. L., Perucho, L., Paciucci, R., Vilardell, J., & LLeonart, M. E. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9460-6 · Cited by 95
Yeh, P.-Y., Chuang, S., Yeh, K., Song, Y., Chang, L. L.-Y., & Cheng, A. (2004) · Oncogene · doi:10.1038/sj.onc.1207426 · Cited by 99
“Loss of p53 function increases genomic instability and promotes tumor progression (Lane, 1992; Gottlieb and Oren, 1996; Ko and Prives, 1996).”
BackgroundSolinas‐Toldo, S., Dürst, M., & Lichter, P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3854 · Cited by 86
The Li-Fraumeni syndrome: An inherited susceptibility to cancer
Evans, S. C., & Lozano, G. (1997) · Molecular Medicine Today · doi:10.1016/s1357-4310(97)01105-2 · Cited by 101
A role for p53 in the frequency and mechanism of mutation
Morris, S. M. (2002) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(01)00075-8 · Cited by 96
Jansson, T. E., Inganäs, M., Sjögren, S., Norberg, T., Lindgren, A., Holmberg, L., & Bergh, J. C. S. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2745 · Cited by 86
Uberti, D. L., Yavin, E., Gil, S., Kameshwar‐Rao, A. S. V. R., Goldfinger, N., & Rotter, V. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00339-8 · Cited by 95
Polkowski, W. P., van Lanschot, J. J. B., ten Kate, F. J. W., Baak, J. P. A., Tytgat, G. N. J., Obertop, H., Voorn, W. J., & Offerhaus, G. J. A. (1995) · Surgical Oncology · doi:10.1016/s0960-7404(10)80021-0 · Cited by 86
Molecular markers for bladder cancer: the road to a multimarker approach
Birkhahn, M., Mitra, A. P., & Côté, R. J. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.12.1717 · Cited by 88
Inflammation and the chemical carcinogen benzo[a]pyrene: Partners in crime
Shi, Q., Godschalk, R., & van Schooten, F. (2017) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2017.08.003 · Cited by 95
Epigenetic modifications affect the rate of spontaneous mutations in a pathogenic fungus
Habig, M., Lorrain, C., Feurtey, A., Komluski, J., & Stukenbrock, E. H. (2021) · Nature Communications · doi:10.1038/s41467-021-26108-y · Cited by 92
Wilder, P. T., Lin, J., Bair, C. L., Charpentier, T. H., Yang, D., Liriano, M. A., Varney, K. M., Lee, A., Oppenheim, A. B., Adhya, S. L., et al. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.08.024 · Cited by 85
Down‐regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity
Zeng, Y., Kulkarni, P., Inoue, T., & Getzenberg, R. H. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22114 · Cited by 85
“In response to DNA damage, induction of p53 protein either causes the cells to arrest in different phases of the cell cycle, or if DNA damage is excessive, p53 leads the cells through apoptosis by regulating the bcl-2 family of genes [Weinberg, 1991; Lane, 1992].”
BackgroundSmall molecule agents targeting the p53‐MDM2 pathway for cancer therapy
Wang, W., & Hu, Y. (2012) · Medicinal Research Reviews · doi:10.1002/med.20236 · Cited by 85
“It has been established that p53, the guardian of the genome, is playing a crucial role in cellular mechanisms like cell cycle arrest, apoptosis, DNA repair, and senescence.(2) Once activated under several kinds of stress like DNA damage, oncogenic activation, and hypoxia, p53 can exert supper antitumor effect via two…”
BackgroundLane, D. P., & Hupp, T. R. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02669-2 · Cited by 86
Self-citationP53 gene mutations: Case study of a clinical marker for solid tumors
Liu, M., & Gelmann, E. P. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.32900 · Cited by 85
Towards an understanding of the role of p53 in adrenocortical carcinogenesis
Wasserman, J. D., Zambetti, G. P., & Malkin, D. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.010 · Cited by 84
“To fulfill its role as ‘‘guardian of the genome’’ (Lane, 1992), p53 coordinates a wide array of cellular processes and, as a result, is reliant on a meticulously refined network of positive and negative regulators.”
Selective and Potent Morpholinone Inhibitors of the MDM2–p53 Protein–Protein Interaction
Gonzalez, A. Z., Eksterowicz, J., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Duquette, J., Fox, B. M., Fu, J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401767k · Cited by 84
Ionizing Radiation-inducible Apoptosis in the Absence of p53 Linked to Transcription Factor EGR-1
Ahmed, M. M., Sells, S. F., Venkatasubbarao, K., Fruitwala, S. M., Muthukkumar, S., Harp, C., Mohiuddin, M., & Rangnekar, V. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.52.33056 · Cited by 84
Ormerod, M. G., O’Neill, C., Robertson, D. M., Kèlland, L. R., & Harrap, K. R. (1996) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050413 · Cited by 84
“Recently, attention has focused on the role of p53 in the response of cells to agents that react with DNA [30].”
BackgroundVersatile functions of p53 protein in multicellular organisms
Chumakov, P. M. (2007) · Biochemistry (Moscow) · doi:10.1134/s0006297907130019 · Cited by 84
Suppression of Glucosylceramide Synthase Restores p53-Dependent Apoptosis in Mutant p53 Cancer Cells
Liu, Y., Patwardhan, G. A., Bhinge, K. N., Gupta, V. K., Gu, X., & Jazwinski, S. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3107 · Cited by 90
Ceilley, R. I. (2010) · Journal of Dermatological Treatment · doi:10.3109/09546634.2010.507704 · Cited by 85
Increased radiosensitivity with chronic hypoxia in four human tumor cell lines
Zölzer, F., & Streffer, C. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02963-2 · Cited by 85
Regulation of p53 protein expression in human breast cancer cell lines
Vojtěšek, B., & Lane, D. P. (1993) · Journal of Cell Science · doi:10.1242/jcs.105.3.607 · Cited by 84
Self-citationBaretton, G. B., Klenk, U., Diebold, J., Schmeller, N., & Löhrs, U. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690390 · Cited by 85
“Its main physiologic function is controlling the integrity the DNA (Lane, 1992).”
Stem cell origins of leukaemia and curability
Greaves, M. F. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.81 · Cited by 84
Evidence for a G2 Checkpoint in p53-Independent Apoptosis Induction by X-Irradiation
Han, Z., Chatterjee, D., He, D. M., Early, J., Pantazis, P., Wyche, J. H., & Hendrickson, E. A. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.11.5849 · Cited by 84
The Memorial Symptom Assessment Scale Short Form (MSAS-SF): Validity and reliability
Chang, V. T., Hwang, S. S., Feuerman, M., Kasimis, B. S., & Thaler, H. T. (2000) · Cancer · doi:10.1002/1097-0142(20000901)89:5<1162::aid-cncr26>3.0.co;2-y · Cited by 455
Pant, V., Xiong, S., Jackson, J. G., Post, S. M., Abbas, H. A., Quintás-Cardama, A., Hamir, A. N., & Lozano, G. (2013) · Genes & Development · doi:10.1101/gad.227249.113 · Cited by 84
“The ubiquitously expressed p53 tumor suppressor is maintained normally in an inactive latent form but functions as the ‘‘guardian of the genome’’ in response to DNA damage (Lane 1992).”
BackgroundTargeting Tumor Suppressor Networks for Cancer Therapeutics
Guo, X. E., Ngo, B., Modrek, A. S., & Lee, W. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106095151 · Cited by 103
Allan, L. A., & Fried, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202931 · Cited by 100
“Although several factors, including the amount of DNA damage incurred (Lane, 1992), the cellular environment (Gottlieb et al., 1994; Canman et al., 1995) and cell type (Lowe et al., 1993; El-Deiry et al., 1994; Attardi et al., 1996) have been proposed to in¯uence cell fate after DNA damage, the…”
BackgroundAhn, E.-Y. E., Pan, G., Vickers, S. M., & McDonald, J. M. (2002) · International Journal of Cancer · doi:10.1002/ijc.10516 · Cited by 83
Intrinsically disordered regions of p53 family are highly diversified in evolution
Xue, B., Brown, C. J., Dunker, A. K., & Uversky, V. N. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.01.012 · Cited by 85
Medicinal Chemistry Strategies to Disrupt the p53–MDM2/MDMX Interaction
Lemos, A., Leão, M., Soares, J., Palmeira, A., Pinto, M., Saraiva, L., & Sousa, M. E. (2016) · Medicinal Research Reviews · doi:10.1002/med.21393 · Cited by 81
Tjalma, W. A. A., Weyler, J., Bogers, J., Pollefliet, C., Baay, M. F. D., Goovaerts, G., Vermorken, J. B., van Dam, P. A., Marck, E. A. V., & Buytaert, P. (2001) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/s0301-2115(00)00541-8 · Cited by 83
Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats
Badie, B., Drazan, K. E., Krama, M. H., Shaked, A. A., & Black, K. L. (1995) · Neurological Research · doi:10.1080/01616412.1995.11740314 · Cited by 83
Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder*1
WAGNER, U., Sauter, G., Moch, H., Novotná, H., Epper, R., Mihatsch, M. J., & Waldman, F. (1995) · Human Pathology · doi:10.1016/0046-8177(95)90086-1 · Cited by 83
Kerr, K. M., Carey, F. A., King, G., & Lamb, D. (1994) · The Journal of Pathology · doi:10.1002/path.1711740404 · Cited by 83
Structure of the rat p53 tumor suppressor gene
Hulla, J. E., & Schneider, R. P. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.3.713 · Cited by 84
Transcriptional Repression of p53 by Human T-cell Leukemia Virus Type I Tax Protein
Uittenbogaard, M. N., Giebler, H. A., Reisman, D., & Nyborg, J. K. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.48.28503 · Cited by 86
A direct effect of activated human p53 on nuclear DNA replication.
Cox, L. S., Hupp, T. R., Midgley, C., & Lane, D. P. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07201.x · Cited by 90
Self-citationLi, J., Wang, P., Long, N., Zhuang, J., Springer, D., Zou, J., Lin, Y., Bleck, C. K. E., Park, J., Kang, J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904979116 · Cited by 91
Acne Transcriptomics: Fundamentals of Acne Pathogenesis and Isotretinoin Treatment
Melnik, B. C. (2023) · Cells · doi:10.3390/cells12222600 · Cited by 100
“As p53, which is called the guardian of the genome [344], plays key roles in the regulation of lipid metabolism [345–350], cell cycle control [351,352], autophagy [232] and apoptosis [351–355], the viral inactivation of p53 via SV40 transfection will certainly cause deviations from normal…”
BackgroundMandl‐Weber, S., Meinel, F. G., Jankowsky, R., Oduncu, F., Schmidmaier, R., & Baumann, P. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08124.x · Cited by 81
“In accordance with downregulation of cyclin D1, cdc25a and Cdk4, levels of p-Rb timedependently declined under resminostat treatment. p53 is a transcription factor crucial for G1 phase checkpoint control and is activated by DNA damage (Lane, 1992).”
BackgroundLukosz, M., Jakob, S., Büchner, N., Zschauer, T.-C., Altschmied, J., & Haendeler, J. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2609 · Cited by 82
“Therefore, p53 has been termed ‘‘guardian of the genome’’ (117).”
A long view of fashions in cancer research
Harris, H. (2005) · BioEssays · doi:10.1002/bies.20263 · Cited by 84
“There are indeed robust and elaborate mechanisms that maintain the stability of the human karyotype,((31,32)) and it is clear that once these break down, as occurs during the growth of a malignant tumour, large numbers of mutations, including cell cycle mutations, are accumulated.”
BackgroundTelomere shortening and the clinicopathologic characteristics of human colorectal carcinomas
Takagi, S., Kinouchi, Y., Hiwatashi, N., Chida, M., Nagashima, F., Takahashi, S., Negoro, K., Shimosegawa, T., & Toyota, T. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991015)86:8<1431::aid-cncr7>3.0.co;2-r · Cited by 47
Mechanism of action of purine analogues in chronic lymphocytic leukaemia
Pettitt, A. R. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04336.x · Cited by 97
“p53 is a tumour suppressor protein that protects the genome from mutation by either eliminating damaged cells through the induction of apoptosis or by facilitating DNA repair through the initiation of cell cycle arrest (Lane, 1992; Levine, 1997).”
BackgroundMolecular Genetics of Head and Neck Cancer
Gleich, L. L., & Salamone, F. N. (2002) · Cancer Control · doi:10.1177/107327480200900502 · Cited by 97
GERMLINE p53 MUTATIONS AND HERITABLE CANCER
Malkin, D. (1994) · Annual Review of Genetics · doi:10.1146/annurev.ge.28.120194.002303 · Cited by 59
Apoptosis and gastrointestinal pharmacology
Pritchard, D. M., & Watson, A. J. M. (1996) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00102-7 · Cited by 90
Association of p53 and WAF1 expression with apoptosis in diffuse alveolar damage.
Guinee, D. G., Fleming, M. V., Hayashi, T., Woodward, M. L., Zhang, J., Walls, J., Koss, M., Ferrans, V. J., & Travis, W. D. (1996) · Europe PMC (PubMed Central) · Cited by 82
Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients.
Falette, N., Paperin, M.-P., Treilleux, I., Gratadour, A.-C., Peloux, N., Mignotte, H., Tooke, N., Löfman, E., Inganäs, M., Bremond, A. G., et al. (1998) · PubMed · Cited by 82
In vivo assay of p53 function in homologous recombination between simian virus 40 chromosomes
Wiesmüller, L., Cammenga, J., & Deppert, W. W. (1996) · Journal of Virology · doi:10.1128/jvi.70.2.737-744.1996 · Cited by 81
van Leeuwen, I., & Laín, S. (2009) · Advances in cancer research · doi:10.1016/s0065-230x(09)02005-3 · Cited by 90
“# 2009 Elsevier Inc. TRODUCTION With more than 48,000 references in PubMed and diverse roles in the modulation of fertility, development, differentiation, and ageing, p53—the “guardian of the genome” (Lane, 1992)—is arguably the most important RESEARCH 0065-230X/09 $35.00 ier Inc.”
BackgroundInfluentialDilution of Irradiated Cell Conditioned Medium and the Bystander Effect
Ryan, L. A., Smith, R. W. P., Seymour, C. B., & Mothersill, C. E. (2008) · Radiation Research · doi:10.1667/rr1141.1 · Cited by 81
“The p53 (TP53) protein is known as the ‘‘guardian of the genome’’ (42) and has been reported to be involved in the repair of radiation-induced DNA damage and the initiation of apoptosis after radiation-induced DNA damage, presumably leading to the elimination of lethally damaged cells from the irradiated population (4…”
BackgroundRaju, U., Gumin, G. J., & Tofilon, P. J. (1999) · Radiation Oncology Investigations · doi:10.1002/(sici)1520-6823(1999)7:3<145::aid-roi2>3.0.co;2-r · Cited by 38
Molecular Abnormalities in Chronic Myeloid Leukemia: Deregulation of Cell Growth and Apoptosis
Bacco, A. D., Keeshan, K., McKenna, S. L., & Cotter, T. G. (2000) · The Oncologist · doi:10.1634/theoncologist.5-5-405 · Cited by 105
The Emerging Landscape of p53 Isoforms in Physiology, Cancer and Degenerative Diseases
Anbarasan, T., & Bourdon, J.-C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246257 · Cited by 83
Ghebranious, N., & Sell, S. (1998) · Hepatology · doi:10.1002/hep.510270211 · Cited by 81
Gene regulation by temperature-sensitive p53 mutants: identification of p53 response genes.
Buckbinder, L., Talbott, R., Seizinger, B. R., & Kley, N. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.22.10640 · Cited by 82
Schover, L. R., Yetman, R. J., Tuason, L. J., Meisler, E., Esselstyn, C. B., Hermann, R. E., Grundfest-Broniatowski, S., & Dowden, R. V. (1995) · Cancer · doi:10.1002/1097-0142(19950101)75:1<54::aid-cncr2820750111>3.0.co;2-i · Cited by 286
Breivik, J., & Gaudernack, G. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60777-0 · Cited by 81
Genetic instability as a consequence of inappropriate entry into and Progression through S-phase
Almasan, A., Linke, S. P., Paulson, T. G., Huang, L.-C., & Wahl, G. M. (1995) · Cancer and Metastasis Reviews · doi:10.1007/bf00690212 · Cited by 91
Hiraki, M., Hwang, S.-Y., Cao, S., Ramadhar, T. R., Byun, S., Yoon, K. W., Lee, J. H., Chu, K., Gurkar, A. U., Kolev, V., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.07.016 · Cited by 81
“Thus, p53 is a tumor suppressor gene and is frequently called the guardian of the genome (Lane, 1992).”
Cruz, I., Napier, S., van der Waal, I., Snijders, P. J. F., Walboomers, J. M. M., Lamey, P. J., Cowan, C. G., Gregg, T. A., Maxwell, P., & Meijer, C. J. L. M. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.2.98 · Cited by 80
Ariyoshi, K., Kawauchi, S., Kaku, T., Nakano, H., & Tsuneyoshi, M. (2000) · Histopathology · doi:10.1046/j.1365-2559.2000.01015.x · Cited by 80
MIF Maintains the Tumorigenic Capacity of Brain Tumor–Initiating Cells by Directly Inhibiting p53
Fukaya, R., Ohta, S., Yaguchi, T., Matsuzaki, Y., Sugihara, E., Okano, H., Saya, H., Kawakami, Y., Kawase, T., Yoshida, K., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1011 · Cited by 77
Bauer, M. R., Jones, R. N., Baud, M. G. J., Wilcken, R., Boeckler, F. M., Fersht, A. R., Joerger, A. C., & Spencer, J. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00315 · Cited by 78
Grabenbauer, G. G., Steininger, H., Meyer, M. F., Fietkau, R., Brunner, T. B., Heinkelmann, P., Hornung, J. A., Iro, H., Spitzer, W. J., Distel, L. V., et al. (1998) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(98)00016-4 · Cited by 84
“The current view is that wild-type p53 delays entry into the S-phase in cases of DNA damage and allows extra time for repair before replication [8,25,28, 49].”
Backgroundp53 Oncoprotein Expression and Proliferation Index in Keratoacanthoma and Squamous Cell Carcinoma
KERSCHMANN, R. L. (1994) · Archives of Dermatology · doi:10.1001/archderm.130.2.181 · Cited by 80
Dodson, M. K., Cliby, W. A., Xu, H., Delacey, K., Hu, S., Keeney, G. L., Li, J., Podratz, K. C., Jenkins, R. B., & Benedict, W. F. (1994) · PubMed · Cited by 80
Bagga, D., Ashley, J. M., Geffrey, S. P., Wang, H.-J., Barnard, R. J., Korenman, S. G., & Heber, D. (1995) · Cancer · doi:10.1002/1097-0142(19951215)76:12<2565::aid-cncr2820761224>3.0.co;2-b · Cited by 104
Tissue-specific inactivation of p53 tumor suppression in the mouse.
Bowman, T., Symonds, H., Gu, L., Yin, C., Oren, M., & Van Dyke, T. (1996) · Genes & Development · doi:10.1101/gad.10.7.826 · Cited by 82
Pathological Role of HDAC8: Cancer and Beyond
Kim, J. Y., Cho, H., Yoo, J. H., Kim, G. W., Jeon, Y. H., Lee, S. W., & Kwon, S. H. (2022) · Cells · doi:10.3390/cells11193161 · Cited by 89
“p53 is often referred to as the “guardian of the genome” and regulates multiple cellular events such as cell cycle progression and apoptosis [64].”
BackgroundThe nucleolus: reviewing oldies to have new understandings
Lo, S. J., Lee, C.-C., & Lai, H.-J. (2006) · Cell Research · doi:10.1038/sj.cr.7310070 · Cited by 81
Nie, J., Xie, P., Liu, L., Xing, G., Chang, Z., Yin, Y., Tian, C., He, F., & Zhang, L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.126920 · Cited by 79
Limitations of Peptide Retro-inverso Isomerization in Molecular Mimicry
Li, C., Pazgier, M., Li, J., Li, C., Liu, M., Zou, G., Li, Z., Chen, J., Tarasov, S. G., Lu, W.-Y., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.116814 · Cited by 79
TRIM25 has a dual function in the p53/Mdm2 circuit
Zhang, P., Elabd, S., Hammer, S., Solozobova, V., Yan, H., Bartel, F., Inoue, S., Henrich, T., Wittbrodt, J., Loosli, F., et al. (2015) · Oncogene · doi:10.1038/onc.2015.21 · Cited by 85
Haley, B., Paunesku, T., Protić, M., & Woloschak, G. E. (2009) · International Journal of Radiation Biology · doi:10.1080/09553000903009548 · Cited by 80
“While p53’s role in cell-cycle checkpoint arrest and the DDR pathway was identified 15 years ago by Lane (1992) and Efeyan and Serrano (2007), the work of the Moumen group on hnRNP K was not carried out until 2003.”
BackgroundPrognostic factors and selection for clinical studies of patients with kidney cancer
Lam, J. S., Klatte, T., Kim, H. L., Patard, J., Breda, A., Zisman, A., Pantuck, A. J., & Figlin, R. A. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.08.003 · Cited by 92
Comparative studies of prostate cancer in Japan versus the United States
Watanabe, M., Nakayama, T., Shiraishi, T., Stemmermann, G. N., & Yatani, R. (2000) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/s1078-1439(00)00092-2 · Cited by 79
Dispersyn, G. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00096-6 · Cited by 79
Bellamy, C. O. C. (1997) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a011628 · Cited by 80
Honma, M., Hayashi, M., & Sofuni, T. (1997) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(96)00223-0 · Cited by 79
p53 inhibits entry into mitosis when DNA synthesis is blocked
Taylor, W. R., Agarwal, M. L., Agarwal, A. M., Stacey, D. W., & Stark, G. R. (1999) · Oncogene · doi:10.1038/sj.onc.1202516 · Cited by 88
“…cells in response to UV or ionizing radiation occurs by the same mechanism that responds to inhibition of DNA synthesis. p53 is essential for maintaining genomic stability, helping to protect mammals from neoplasia (reviewed in Agarwal et al., 1998b; Levine, 1997; Ko and Prives, 1996; Lane, 1992).”
BackgroundTop, B., Mooi, W. J., Klaver, S. G., Boerrigter, L., Wisman, P., Elbers, H. R. J., Visser, S., & Rodenhuis, S. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640203 · Cited by 79
The Paradox of p53: What, How, and Why?
Aylon, Y., & Oren, M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026328 · Cited by 79
“Thus, the celebrated “guardian of the genome” (Lane 1992) is evolving into the “guardian of homeostasis.””
Backgroundp53: key conductor of all anti-acne therapies
Melnik, B. C. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1297-2 · Cited by 78
p53 Activity Results in DNA Replication Fork Processivity
Klusmann, I., Rodewald, S., Müller, L., Friedrich, M., Wienken, M., Li, Y., Schulz‐Heddergott, R., & Dobbelstein, M. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.036 · Cited by 86
Curcumin’s Beneficial Effects on Neuroblastoma: Mechanisms, Challenges, and Potential Solutions
Zhai, K., Brockmueller, A., Kubatka, P., Shakibaei, M., & Büsselberg, D. (2020) · Biomolecules · doi:10.3390/biom10111469 · Cited by 84
Khan, A. A., Liu, X., Yan, X., Tahir, M., Ali, S., & Huang, H. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09952-0 · Cited by 83
Lin, K., Rockliffe, N., Johnson, G. G., Sherrington, P. D., & Pettitt, A. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210893 · Cited by 91
“In doing so it fulfils an important function in regulating cell growth and survival in the face of cellular stresses and plays a pivotal role in maintaining genomic stability (Lane, 1992).”
BackgroundElectroanalysis of Plant Thiols
Supalkova, V., Huska, D., Diopan, V., Hanustiak, P., Zitka, O., Stejskal, K., Baloun, J., Pikula, J., Havel, L., Zehnalek, J., et al. (2007) · Sensors · doi:10.3390/s7060932 · Cited by 78
Muscle ankyrin repeat proteins: their role in striated muscle function in health and disease
Kojić, S., Radojkovic, D. P., & Faulkner, G. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.643857 · Cited by 85
Oxidative stress-mediated biomolecular damage and inflammation in tumorigenesis.
Sesti, F., Tsitsilonis, O., Kotsinas, A., & Trougakos, I. P. (2012) · PubMed · Cited by 94
Functions of p53 in pluripotent stem cells
Fu, X., Wu, S., Li, B., Xu, Y., & Liu, J. (2019) · Protein & Cell · doi:10.1007/s13238-019-00665-x · Cited by 100
“While the complex roles of p53 remain to be elucidated, p53 is known as “the guardian of the genome” and is required to maintain genomic stability of mammalian cells (Lane, 1992; Levine, 1997).”
BackgroundSgambato, A., Migaldi, M., Faraglia, B., Garagnani, L., Romano, G. D., Gaetani, C. D., Ferrari, P., Capelli, G., Trentini, G. P., & Cittadini, A. R. M. (1999) · PubMed · Cited by 82
Metadata
- Authors
- Lane, D. P.
- Affiliations
- University of Dundee (GB)
- Corresponding author
- Lane, D. P.
- ORCID
- Lane, D. P.
- Venue
- Nature
- Published
- 1992-07
- Volume
- 358
- Issue
- 6381
- Pages
- 15-16
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2012053348
- Cited by
- 5,138
- References
- 19
- Citations by year
- 2026: 84 · 2025: 92 · 2024: 122 · 2023: 112 · 2022: 135 · 2021: 142 · 2020: 150 · 2019: 128 · 2018: 140 · 2017: 138 · 2016: 142 · 2015: 135 · 2014: 150 · 2013: 142 · 2012: 143
- FWCI
- 97.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- TP53, p53, TP53 mutation, cancer, genome stability, tumor suppressor
- MeSH terms
- Animals, Chromosome Mapping, DNA Damage, DNA Repair, DNA-Binding Proteins, Gene Expression Regulation, Humans, Oncogenes, Transcription Factors, Genes, Tumor Suppressor, Tumor Suppressor Protein p53
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.